$YCBD
cbdMD, Inc. Stock $ycbd

$ycbd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000143774924003902 Filed on February 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2022 Q4
Revenue	$4.377M	$5.375M	$6.085M
YoY Change	-29.86%	-11.66%	-34.72%
Cost Of Revenue	$1.796M	$1.818M	$2.517M
YoY Change	-19.27%	-27.79%	-41.84%
Gross Profit	$2.581M	$3.557M	$3.568M
YoY Change	-35.73%	-0.29%	-28.55%
Gross Profit Margin	58.97%	66.18%	58.63%
Selling, General & Admin	$3.379M	$3.426M	$5.442M
YoY Change	-15.46%	-37.06%	-49.83%
% of Gross Profit	130.93%	96.29%	152.54%
Research & Development	$2.100K	$4.630K
YoY Change
% of Gross Profit	0.08%	0.13%
Depreciation & Amortization	$290.6K	$110.9K	$100.1K
YoY Change	4.77%	10.74%	-70.62%
% of Gross Profit	11.26%	3.12%	2.81%
Operating Expenses	$4.132M	$4.623M	$6.729M
YoY Change	-8.82%	-31.29%	-43.71%
Operating Profit	-$1.551M	-$1.066M	-$4.046M
YoY Change	10.73%	-73.66%	-83.91%
Interest Expense	-$1.464M	-$420.00	$29.12K
YoY Change	74997.44%	-101.44%	-179.61%
% of Operating Profit
Other Income/Expense, Net	$0.00		$0.00
YoY Change	-100.0%		-100.0%
Pretax Income	-$3.011M	-$996.5K	-$3.956M
YoY Change	125.21%	-74.81%	-79.35%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.011M	-$996.5K	-$3.956M
YoY Change	125.21%	-74.81%	-79.35%
Net Earnings / Revenue	-68.79%	-18.54%	-65.01%
Basic Earnings Per Share	-$1.35	-$0.67	-$0.08
Diluted Earnings Per Share	-$1.35	-$0.67	-$0.08
COMMON SHARES
Basic Shares Outstanding	3.045M	2.961M	60.68M
Diluted Shares Outstanding	2.961M		60.36M

Balance Sheet

Concept	2024 Q1	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.105M	$1.505M	$4.353M
YoY Change	22.51%	-65.43%	-78.97%
Cash & Equivalents	$2.105M	$1.505M	$3.353M
Short-Term Investments			$1.000M
Other Short-Term Assets	$1.263M	$1.205M	$1.587M
YoY Change	-53.82%	-24.11%	-47.19%
Inventory	$3.452M	$3.743M	$4.861M
Prepaid Expenses
Receivables	$868.2K	$576.9K	$265.5K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.410M	$7.366M	$11.53M
YoY Change	-26.97%	-36.11%	-61.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$668.0K	$790.3K	$900.6K
YoY Change	-16.31%	-12.24%	-64.04%
Goodwill
YoY Change
Intangibles	$2.873M	$3.046M	$17.56M
YoY Change	-83.37%	-82.65%	-5.94%
Long-Term Investments	$700.0K	$700.0K	$1.400M
YoY Change	-50.0%	-50.0%
Other Assets	$132.2K	$132.2K	$138.7K
YoY Change	-4.69%	-4.69%	-65.98%
Total Long-Term Assets	$7.140M	$7.729M	$24.20M
YoY Change	-69.67%	-68.06%	-65.26%
TOTAL ASSETS
Total Short-Term Assets	$7.410M	$7.366M	$11.53M
Total Long-Term Assets	$7.140M	$7.729M	$24.20M
Total Assets	$14.55M	$15.10M	$35.73M
YoY Change	-56.8%	-57.75%	-64.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.291M	$1.567M	$1.690M
YoY Change	-3.46%	-7.27%	-54.01%
Accrued Expenses	$1.282M	$3.102M	$2.650M
YoY Change	-39.16%	17.06%	-12.43%
Deferred Revenue	$468.5K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$9.760K
YoY Change	-100.0%	-100.0%	-83.86%
Total Short-Term Liabilities	$6.937M	$5.972M	$5.552M
YoY Change	48.24%	7.55%	-17.87%
LONG-TERM LIABILITIES
Long-Term Debt	$2.702M	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00	$2.087M	$3.584M
YoY Change	-100.0%	-41.77%	-55.61%
Total Long-Term Liabilities	$4.527M	$2.087M	$3.584M
YoY Change	40.65%	-41.77%	-56.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.937M	$5.972M	$5.552M
Total Long-Term Liabilities	$4.527M	$2.087M	$3.584M
Total Liabilities	$11.46M	$8.058M	$9.136M
YoY Change	45.14%	-11.8%	-38.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$180.4M	-$176.4M	-$152.4M
YoY Change	16.58%	15.74%	62.97%
Common Stock	$3.045K	$2.961K	$60.71K
YoY Change	108.99%	-95.12%	4.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.087M	$7.037M	$26.59M
YoY Change
Total Liabilities & Shareholders Equity	$14.55M	$15.10M	$35.73M
YoY Change	-56.8%	-57.75%	-64.03%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.011M	-$996.5K	-$3.956M
YoY Change	125.21%	-74.81%	-79.35%
Depreciation, Depletion And Amortization	$290.6K	$110.9K	$100.1K
YoY Change	4.77%	10.74%	-70.62%
Cash From Operating Activities	-$704.1K	-$105.9K	-$2.064M
YoY Change	-59.39%	-94.87%	-62.25%
INVESTING ACTIVITIES
Capital Expenditures	-$4.620K	$184.6K	$177.4K
YoY Change	-95.49%	4.1%	-176.77%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$4.620K	-$184.6K	-$177.4K
YoY Change	-99.58%	4.1%	-23.23%
FINANCING ACTIVITIES
Cash Dividend Paid		$1.001M	$1.001M
YoY Change		0.0%	0.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.300M	-$2.501K	-$1.126M
YoY Change	-229.63%	-99.78%	10.92%
NET CHANGE
Cash From Operating Activities	-704.1K	-$105.9K	-$2.064M
Cash From Investing Activities	4.620K	-$184.6K	-$177.4K
Cash From Financing Activities	1.300M	-$2.501K	-$1.126M
Net Change In Cash	600.6K	-$293.0K	-$3.368M
YoY Change	-136.75%	-91.3%	-49.85%
FREE CASH FLOW
Cash From Operating Activities	-$704.1K	-$105.9K	-$2.064M
Capital Expenditures	-$4.620K	$184.6K	$177.4K
Free Cash Flow	-$699.5K	-$290.5K	-$2.242M
YoY Change	-57.12%	-87.04%	-57.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5000000
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5000000
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2961056
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2961056
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2960573
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2960573
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2961056
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2960573
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	dei	Document Type DocumentType	10-Q
CY2023Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q4	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	dei	Entity File Number EntityFileNumber	001-38299
CY2023Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NC
CY2023Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3414576
CY2023Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	8845 Red Oak Blvd
CY2023Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlotte
CY2023Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
CY2023Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	28217
CY2023Q4	dei	City Area Code CityAreaCode	704
CY2023Q4	dei	Local Phone Number LocalPhoneNumber	445-3060
CY2023Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3045092
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1504844	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1797860	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1102180	usd
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1216090	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	3554395	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	4052972	usd
CY2023Q4	ycbd	Prepaid Inventory PrepaidInventory	188250	usd
CY2023Q3	ycbd	Prepaid Inventory PrepaidInventory	182675	usd
CY2023Q4	ycbd	Prepaid Sponsorship PrepaidSponsorship	29473	usd
CY2023Q3	ycbd	Prepaid Sponsorship PrepaidSponsorship	70061	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	986821	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	750383	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7365963	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	8070041	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	790349	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	716579	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3060405	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3350865	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	132203	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	138708	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3046248	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3219090	usd
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	700000	usd
CY2023Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	700000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	7729205	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	8125242	usd
CY2023Q4	us-gaap	Assets Assets	15095168	usd
CY2023Q3	us-gaap	Assets Assets	16195283	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1566633	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1906319	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3102468	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1484441	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1302663	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1277089	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2492	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5971764	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4670341	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2066050	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2403286	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	20611	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	90363	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2086661	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2493658	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8058425	usd
CY2023Q3	us-gaap	Liabilities Liabilities	7163999	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2961	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2961	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	183389556	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	183387095	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176360774	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-174363772	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7036743	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	9031284	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15095168	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16195283	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5375630	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6240526	usd
CY2023Q4	ycbd	Sales Allowances SalesAllowances	225	usd
CY2022Q4	ycbd	Sales Allowances SalesAllowances	155308	usd
CY2023Q4	us-gaap	Revenues Revenues	5375405	usd
CY2022Q4	us-gaap	Revenues Revenues	6085218	usd
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	1817907	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	2517452	usd
CY2023Q4	us-gaap	Gross Profit GrossProfit	3557498	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	3567766	usd
CY2023Q4	ycbd	Operating Expenses Excluding Impairment OperatingExpensesExcludingImpairment	4623333	usd
CY2022Q4	ycbd	Operating Expenses Excluding Impairment OperatingExpensesExcludingImpairment	7613947	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1065835	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4046181	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-69752	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-61000	usd
CY2023Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-418	usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	29119	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-996501	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3956062	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-996501	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3956062	usd
CY2023Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
CY2022Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000502	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1997002	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4956564	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.7
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2960945
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1341277
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-996501	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3956062	usd
CY2023Q4	ycbd	Comprehensive Income Loss Net Of Tax Attributable To Parent Before Income Adjustments ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments	-996501	usd
CY2022Q4	ycbd	Comprehensive Income Loss Net Of Tax Attributable To Parent Before Income Adjustments ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments	-3956062	usd
CY2023Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
CY2022Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000502	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1997002	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4956564	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-996501	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3956062	usd
CY2023Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1772	usd
CY2022Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	79446	usd
CY2023Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	689	usd
CY2022Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	43449	usd
CY2023Q4	ycbd	Write Off Of Prepaid Assets WriteOffOfPrepaidAssets	0	usd
CY2022Q4	ycbd	Write Off Of Prepaid Assets WriteOffOfPrepaidAssets	884892	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172842	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	277354	usd
CY2023Q4	us-gaap	Depreciation Depreciation	110864	usd
CY2022Q4	us-gaap	Depreciation Depreciation	100112	usd
CY2023Q4	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022Q4	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-69752	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-61000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	290459	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	276636	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-67169	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-549111	usd
CY2023Q4	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-6505	usd
CY2022Q4	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-105898	usd
CY2023Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-498577	usd
CY2022Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	434695	usd
CY2023Q4	ycbd	Increase Decrease In Prepaid Inventory Total IncreaseDecreaseInPrepaidInventoryTotal	5575	usd
CY2022Q4	ycbd	Increase Decrease In Prepaid Inventory Total IncreaseDecreaseInPrepaidInventoryTotal	-340799	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	195850	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	226670	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	142292	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	39204	usd
CY2023Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-311661	usd
CY2022Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-287547	usd
CY2023Q4	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	182290	usd
CY2022Q4	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	203341	usd
CY2023Q4	ycbd	Collection On Discontinued Operations Accounts Receivable CollectionOnDiscontinuedOperationsAccountsReceivable	0	usd
CY2022Q4	ycbd	Collection On Discontinued Operations Accounts Receivable CollectionOnDiscontinuedOperationsAccountsReceivable	1375	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-105880	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2064357	usd
CY2023Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	184635	usd
CY2022Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	177370	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-184635	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-177370	usd
CY2023Q4	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-2501	usd
CY2022Q4	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-125341	usd
CY2023Q4	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	-0	usd
CY2022Q4	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	1000502	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2501	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1125843	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-293016	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3367570	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1797860	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6720234	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1504844	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3352664	usd
CY2023Q4	us-gaap	Interest Paid Net InterestPaidNet	11614	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	2638	usd
CY2023Q4	ycbd	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	1000501	usd
CY2022Q4	ycbd	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	0	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	9031284	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	689	usd
CY2023Q4	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000501	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-996501	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7036743	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	31424431	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	43449	usd
CY2022Q4	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000502	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3956062	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26590761	usd
CY2023Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s condensed consolidated financial statements have been prepared in accordance with US Generally Accepted Accounting Principles ("GAAP") and requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying condensed consolidated financial statements include, but are <em style="font: inherit;">not</em> limited to, allowances for doubtful accounts, inventory valuation reserves, expected sales returns and allowances, certain assumptions related to the valuation of investments other securities, acquired intangibles and long-lived assets and the recoverability of intangible and long-lived assets and income taxes, including deferred tax valuation allowances and reserves for estimated tax liabilities, and contingent liability is a material estimate. Actual results could differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company continues to monitor macroeconomic conditions to remain flexible and to optimize and evolve its business as appropriate.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	114882	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	42180	usd
CY2023Q4	ycbd	Merchantprocessingfee Merchantprocessingfee	0.025	pure
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	576901	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	585345	usd
CY2023Q4	us-gaap	Revenues Revenues	5375405	usd
CY2022Q4	us-gaap	Revenues Revenues	6085218	usd
CY2023Q4	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Concentrations</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers <em style="font: inherit;">$250,000</em> for substantially all depository accounts. The Company from time to time <em style="font: inherit;"> may </em>have amounts on deposit in excess of the insured limits. The Company had a $0.9 million uninsured balance at <em style="font: inherit;"> December 31, 2023</em> and a $1.2 million uninsured balance at <em style="font: inherit;"> September 30, 2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did <span style="-sec-ix-hidden:c106290753">not</span> have any customers that represented a significant amount of our sales for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2023</em>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0.9	usd
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1.2	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	187701	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	126742	usd
CY2023Q4	ycbd	Prepaid Inventory PrepaidInventory	188250	usd
CY2023Q3	ycbd	Prepaid Inventory PrepaidInventory	182675	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3742645	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	4235647	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-996501	usd
CY2023Q4	ycbd	Working Capital WorkingCapital	-1394198	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2384087	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2782680	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1358009	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1397034	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2359854	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2175219	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1569505	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1458640	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	790349	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	716579	usd
CY2023Q4	us-gaap	Depreciation Excluding Lessor Asset Under Operating Lease DepreciationExcludingLessorAssetUnderOperatingLease	110864	usd
CY2022Q4	us-gaap	Depreciation Excluding Lessor Asset Under Operating Lease DepreciationExcludingLessorAssetUnderOperatingLease	100112	usd
CY2023Q4	ycbd	Finitelived Intangible Asset Accumulated Impairment FinitelivedIntangibleAssetAccumulatedImpairment	17405000	usd
CY2023Q3	ycbd	Finitelived Intangible Asset Accumulated Impairment FinitelivedIntangibleAssetAccumulatedImpairment	17504000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2601163	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2329321	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3046248	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3219090	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	518526	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	688757	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	660040	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	660040	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	496223	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	22662	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3046248	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y4M28D
CY2023Q4	ycbd	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod	0
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Payments Of Dividends PaymentsOfDividends	1000501	usd
CY2022Q4	us-gaap	Payments Of Dividends PaymentsOfDividends	1000502	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2961056
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2960573
CY2023Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	39455
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	41765
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	144.43
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	41765
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	144.43
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	40098
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	149.97
CY2023Q4	ycbd	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q4	ycbd	Class Of Warrant Or Right Exercises In Period ClassOfWarrantOrRightExercisesInPeriod	-0
CY2023Q4	ycbd	Class Of Warrant Or Right Exercises In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q4	ycbd	Class Of Warrant Or Right Forfeitures In Period ClassOfWarrantOrRightForfeituresInPeriod	-0
CY2023Q4	ycbd	Class Of Warrant Or Right Forfeitures In Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q4	ycbd	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	50309
CY2023Q4	ycbd	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	37.75
CY2023Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	332124	usd
CY2023Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	353326	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M7D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0466	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1068284	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1159949	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1092297	usd
CY2023Q4	ycbd	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	280565	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3601095	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	232382	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3368713	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-996501	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3956062	usd
CY2023Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
CY2022Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000502	usd
CY2023Q4	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-1997002	usd
CY2022Q4	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-4956564	usd
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2960945
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1341277
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.7
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	4600000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd

Files In Submission

Name	View Source	Status
0001437749-24-003902-index-headers.html	Edgar Link	pending
0001437749-24-003902-index.html	Edgar Link	pending
0001437749-24-003902.txt	Edgar Link	pending
0001437749-24-003902-xbrl.zip	Edgar Link	pending
cbdmdproducts.jpg	Edgar Link	pending
ex_606723.htm	Edgar Link	pending
ex_606724.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
petproducts.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ycbd-20231231.xsd	Edgar Link	pending
ycbd20231231_10q.htm	Edgar Link	pending
ycbd_10qimg1.jpg	Edgar Link	pending
ycbd_10qimg5.jpg	Edgar Link	pending
ycbd-20231231_cal.xml	Edgar Link	unprocessable
ycbd-20231231_lab.xml	Edgar Link	unprocessable
ycbd-20231231_pre.xml	Edgar Link	unprocessable
ycbd-20231231_def.xml	Edgar Link	unprocessable
ycbd20231231_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YCBD
cbdMD, Inc. Stock $ycbd

2024 Q1 Form 10-Q Financial Statement

#000143774924003902 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YCBD cbdMD, Inc. Stock $ycbd

2024 Q1 Form 10-Q Financial Statement

#000143774924003902 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YCBD
cbdMD, Inc. Stock $ycbd